# A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

> **NCT01146574** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 50 (actual)

## Conditions studied

- Anemia

## Interventions

- **BIOLOGICAL:** Sotatercept
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01146574
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-30
- **Primary completion:** 2016-03-07
- **Final completion:** 2016-03-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01146574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01146574, "A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01146574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*